Zimmer Biomet (NYSE:ZBH) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of $7.60-$7.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.80. The company issued revenue guidance of $7.94-$8.09 billion, compared to the consensus revenue estimate of $7.96 billion.
Zimmer Biomet stock traded up $4.51 during trading hours on Thursday, reaching $115.10. The stock had a trading volume of 3,070,227 shares, compared to its average volume of 1,308,704. The firm has a market cap of $22,232.40, a PE ratio of 14.33, a price-to-earnings-growth ratio of 1.91 and a beta of 1.17. Zimmer Biomet has a 52 week low of $104.28 and a 52 week high of $133.49. The company has a quick ratio of 0.81, a current ratio of 1.50 and a debt-to-equity ratio of 0.76.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.89 by $0.02. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.13 EPS. sell-side analysts expect that Zimmer Biomet will post 7.8 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 11.96%.
ZBH has been the topic of a number of recent analyst reports. SunTrust Banks raised their price target on shares of Zimmer Biomet to $142.00 and gave the stock a buy rating in a report on Monday, January 29th. Raymond James initiated coverage on shares of Zimmer Biomet in a report on Thursday, March 15th. They issued an outperform rating and a $135.00 price target on the stock. BMO Capital Markets reissued a buy rating and issued a $144.00 price target on shares of Zimmer Biomet in a report on Tuesday, January 30th. Morgan Stanley cut their price target on shares of Zimmer Biomet from $150.00 to $148.00 and set an overweight rating on the stock in a report on Monday, February 26th. Finally, Cantor Fitzgerald reissued a buy rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $138.80.
In other Zimmer Biomet news, insider Bryan C. Hanson purchased 25,077 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was bought at an average cost of $119.68 per share, with a total value of $3,001,215.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of Zimmer Biomet stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. Company insiders own 0.71% of the company’s stock.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.